Nonsteroidal anti-inflammatory drugs and 5-HT3 serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia

Journal of Clinical Psychiatry

Volumn 75, Issue 7, 2014, Pages

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COGNITIVE DEFECT; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; GILLES DE LA TOURETTE SYNDROME; HUMAN; INFLAMMATION; MENTAL DISEASE; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MALE; SCHIZOPHRENIA; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; YOUNG ADULT;

EID: 84905278490     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14f09292     Document Type: Article

References (14)

1. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296-1306.
2. Andrade C. Famotidine augmentation in schizophrenia: hope or hype? J Clin Psychiatry. 2013;74(9):e855-e858.
3. Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013;11(3):107-117.
4. Feigenson KA, Kusnecov AW, Silverstein SM. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014;38:72-93.
5. Zakharyan R, Boyajyan A. Inflammatory cytokine network in schizophrenia. World J Biol Psychiatry. 2014;15(3):174-187.
6. Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry. 2014;75(4):292-299.
7. Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets. 2007;11(4):527-540.
8. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113(2):296-320. (Pubitemid 46149046)
9. Sirota P, Mosheva T, Shabtay H, et al. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry. 2000;157(2):287-289. (Pubitemid 30080916)
10. Toren P, Weizman A, Ratner S, et al. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(4):499-503. (Pubitemid 40593579)
11. Kishi T, Mukai T, Matsuda Y, et al. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med. 2014;16(1):61-69.
12. Sridhar N, Veeranjaneyulu A, Arulmozhi DK, et al. 5-HT3 receptors in selective animal models of cognition. Indian J Exp Biol. 2002;40(2):174-180. (Pubitemid 34147280)
13. Costall B, Naylor RJ. 5-HT3 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3(1):27-37.
14. Nitta M, Kishimoto T, Müller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39(6):1230-1241.